Sign In
Buy ABUS
$4.26
-0.220 (-4.91%)
At Close: Jun 02, 2026
Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript
02:00pm, Thursday, 01'st Aug 2024
Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q2 2024 Earnings Conference Call August 1, 2024 8:45 AM ET Company Participants Lisa Caperelli - VP, Investor Relations Michael McElhaugh - Interim Preside
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
09:40am, Thursday, 01'st Aug 2024
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.10 per share a year ago.
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07:30am, Thursday, 01'st Aug 2024
End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
07:30am, Thursday, 18'th Jul 2024
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fun
Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity
05:29am, Friday, 05'th Jul 2024
Arbutus Biopharma's three-pronged strategy targets cHBV by suppressing HBV DNA, reducing viral antigens, and boosting immune response. Imdusiran (AB-729) shows promise in Phase 2 trials, potentially l
Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
11:15am, Thursday, 06'th Jun 2024
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress
Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
02:30am, Wednesday, 05'th Jun 2024
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were
Arbutus Distributors Ltd. News Release
09:50am, Monday, 03'rd Jun 2024
VANCOUVER, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- Mr. Peter Bull and Arbutus Distributors Ltd. (“Arbutus”), a private investment and holding company controlled by Mr. Bull, announced
Arbutus to Participate in Jefferies Global Healthcare Conference
07:30am, Wednesday, 29'th May 2024
WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a func
Arbutus to Present Imdusiran Data at EASL Congress 2024
02:00am, Wednesday, 22'nd May 2024
WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
09:00am, Friday, 17'th May 2024
NEW YORK--(BUSINESS WIRE)--Whitefort Capital Management, LP (together with its affiliates, “Whitefort Capital,” “us” or “we”), which is a long-term investor and the second largest sharehol
Arbutus to Participate in Two Upcoming Investor Conferences
07:30am, Tuesday, 07'th May 2024
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a func
Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript
01:15pm, Thursday, 02'nd May 2024
Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q1 2024 Earnings Conference Call May 2, 2024 8:45 AM ET Company Participants Lisa Caperelli - Vice President, Investor Relations Mike McElhaugh - Interim P
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
09:46am, Thursday, 02'nd May 2024
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.10 per share a year ago.
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
07:30am, Thursday, 02'nd May 2024
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024
